Home Made Adefovir Dipivoxil Therapy in Patients with HBeAg-positive Chronic Hepatitis B. A Multi-Center Randomized Double Blind Placebo-Controlled Clinical Trial

茅益民,曾民德,魏来,谢青,陆志檬,牛俊奇,陈亚岗,雷秉钧,张鸿飞,杨积明,李军,唐勤,吴国祥,曹爱平

DOI: https://doi.org/10.3969/j.issn.1008-1704.2007.05.007

2007-01-01

Abstract:Objective To evaluate the efficacy and safety of the home made Adefovir Dipivoxil(YouHeDing)10 mg/d in the 48-weeks treatment of chronic hepatitis B patients with HBeAg positive in China.Methods Study design is a multi-center,randomized double blind,placebo controlled study.240 Chinese patients were randomized assigned in a 2:1 ratio to receive either YouHeDing or placebo for the first 12 weeks than a patients received open label YouHeDin therapy for the week 12～36.In the last 12 weeks phase spatients who received YouHeDin in the initial 12 week phase were re-randomized in a 1:3 ratio to receive either placebo or YouHeDin.Patients who initially received placebo continued to receive open-label YouHeDin.The primary efficacy endpoint in this study was the log10 reduction of serum HBV DNA from baseline.Secondary endpoints were the rate of patients ALT normalization and the rate of patients with HBeAg loss and HBeAg seroconversion.Results At week 12,the median serum HBV DNA reduction from baseline in group A and B were 2.43 log_ 10 copies/ml and 2.54 log_ 10 copies/ml,both significantly greater than group C(P0.05).At week 36,the median serum HBV DNA reduction from baseline in group A、B and C were 3.57 log_ 10 copies/ml、3.24 log_ 10 copies/ml and 3.29 log_ 10 copies/ml.At week 48,the median serum HBV DNA reduction from baseline in group B and C were 3.58 log_ 10 copies/ml and 3.38 log_ 10 copies/ml.Whereas the median serum HBV DNA level return to 7.37 log_ 10 copies/ml in group A.At week 12,the rate of HBV DNA undetectable in group A and B were 17.50% and 25.83%,significantly higher than 1.25% in group C(P0.05).At week 36,the rate of HBV DNA undetectable in group A、B and C were 37.50%、26.67% and 28.75%.No difference were found between the three groups.At week 48,the rate of HBV DNA undetectable in group B and C were continuously raised to 34.17%and 31.25%,but decreased to 7.50% in group A.At week 48,the rate of ALT normalization in group B and C were continuously raised to 75.25% and 64.06%.The rate of ALT normalization in group A decreased from 75.68% at week 36 to 28.57%.The rate of HBeAg loss and HBeAg seroconversion in group B were 6.42%and 4.55%.Five serious adverse events were not related to the study drug.There were no significant changes of creatinine or serum phosphorus level from baseline.Conclusion YouHeDin 10 mg once daily was safe,and effective in patients with HBeAg-positive chronic hepatitis B.